Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13020354 http://scihub22266oqcxt.onion/10.3390/v13020354 33672333!7926471!33672333     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (2): ä Nephropedia Template TP {{tp|p=33672333|t=2021. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro |pdf=|usr=}}{{33672333}} gab.com Text Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33672333 #FOAvip A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drug repurposing embodies a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested seven compounds for their ability to reduce replication of human coronavirus (HCoV)-229E, another member of the coronavirus family. Among these seven drugs tested, four of them, namely rapamycin, disulfiram, loperamide and valproic acid, were highly cytotoxic and did not warrant further testing. In contrast, we observed a reduction of the viral titer by 80% with resveratrol (50% effective concentration (EC50) = 4.6 microM) and lopinavir/ritonavir (EC50 = 8.8 microM) and by 60% with chloroquine (EC50 = 5 microM) with very limited cytotoxicity. Among these three drugs, resveratrol was less cytotoxic (cytotoxic concentration 50 (CC50) = 210 microM) than lopinavir/ritonavir (CC50 = 102 microM) and chloroquine (CC50 = 67 microM). Thus, among the seven drugs tested against HCoV-229E, resveratrol demonstrated the optimal antiviral response with low cytotoxicity with a selectivity index (SI) of 45.65. Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19. Twit Text FOAVip Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33672333 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33672333 #FOAvip English Wikipedia <ref>{{Cite pmid|33672333}}</ref> Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro #MMPMID33672333 Pasquereau S; Nehme Z; Haidar Ahmad S; Daouad F; Van Assche J; Wallet C; Schwartz C; Rohr O; Morot-Bizot S; Herbein G Viruses 2021[Feb]; 13 (2): ä PMID33672333show ga A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drug repurposing embodies a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested seven compounds for their ability to reduce replication of human coronavirus (HCoV)-229E, another member of the coronavirus family. Among these seven drugs tested, four of them, namely rapamycin, disulfiram, loperamide and valproic acid, were highly cytotoxic and did not warrant further testing. In contrast, we observed a reduction of the viral titer by 80% with resveratrol (50% effective concentration (EC50) = 4.6 microM) and lopinavir/ritonavir (EC50 = 8.8 microM) and by 60% with chloroquine (EC50 = 5 microM) with very limited cytotoxicity. Among these three drugs, resveratrol was less cytotoxic (cytotoxic concentration 50 (CC50) = 210 microM) than lopinavir/ritonavir (CC50 = 102 microM) and chloroquine (CC50 = 67 microM). Thus, among the seven drugs tested against HCoV-229E, resveratrol demonstrated the optimal antiviral response with low cytotoxicity with a selectivity index (SI) of 45.65. Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19. |Antiviral Agents/*pharmacology[MESH] |Cell Line[MESH] |Chloroquine/pharmacology[MESH] |Coronavirus 229E, Human/*drug effects/physiology[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Lopinavir/pharmacology[MESH] |Male[MESH] |Resveratrol/*pharmacology[MESH] |Ritonavir/*pharmacology[MESH] |SARS-CoV-2/*drug effects/physiology[MESH] |Viral Load[MESH]Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication (epmc).pdf DeepDyve Pubget Overpricing